Kissei Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Kissei Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Kissei Pharmaceutical Co Ltd Strategy Report
- Understand Kissei Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Kissei Pharmaceutical Co Ltd (Kissei) discovers, develops, manufactures, and sells pharmaceutical products. The company's pharmaceutical products include urological medicine, metabolic endocrinology medicine, drugs for kidney and dialysis department, drugs for obstetrics and gynecology, ophthalmic medicine and rare disease medicine. It also develops and sells health foods including protein-controlled food, energy supply food, calorie-controlled food, and elderly-controlled food. Kissei conducts research to develop novel drugs and improve existing drugs and provide superior drugs to people worldwide. The company has sales offices across Japan and an overseas subsidiary in New Jersey, the US. Kissei is headquartered in Matsumoto, Japan.
Headquarters
Japan
Address
19-48, Yoshino, Matsumoto-Shi, Nagano, 399-8710
Website
www.kissei.co.jp
Telephone
81 263 259081
No of Employees
1,795
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4547 (TYO)
Revenue (2023)
$498.6M
3.2%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
-18.5%
(2023 vs 2022)
Market Cap*
$1.1B
Net Profit Margin (2023)
XYZ
-21.1%
(2023 vs 2022)
* As of and is in US$
Kissei Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline (In-House): | Beova |
| Avacopan/CCX168 - Microscopic polyangiitis/Granulomatosis with polyangiitis | Urief |
| Rovatirelin/ KPS-0373 - Spinocerebellar Ataxia | Minirin Melt |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In July, the company introduced Makya, Iktos Software as a Service Platform for AI-driven drug discovery. |
| 2023 | New Products/Services | In April, the company launched Oral Platelet Destruction Inhibitor Tavaris Tablets 100mg and 150mg. |
| 2022 | New Products/Services | In June ,the company launched Tavneos Capsules of 10mg for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis. |
Competitor Comparison
| Key Parameters | Kissei Pharmaceutical Co Ltd | Tsumura & Co | Mochida Pharmaceutical Co Ltd | Maruho Co Ltd | Kaken Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Matsumoto-Shi | Minato-Ku | Shinjuku-Ku | Kita | Bunkyo-Ku |
| State/Province | Nagano | Tokyo | Tokyo | Osaka | Tokyo |
| No. of Employees | 1,795 | 4,032 | 1,529 | 1,547 | 1,130 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mutsuo Kanzawa | Chairman; Chief Executive Officer | Executive Board | 2014 | - |
| Yasuo Takehana | Chief Operating Officer; President; Director | Executive Board | 2022 | 61 |
| Takahide Kitahara | Director; Managing Director | Executive Board | 2022 | 60 |
| Keiji Miyazawa | Director; General Manager, Research Division | Executive Board | 2022 | - |
| Hiroshi Noake | General Manager - Sales and Marketing Division; Director | Executive Board | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward